ClinicalTrials.gg
CompletedNCT06739577Updated Dec 18, 2024

Show Me How You Move and I Will Tell You Who You Are

An observational study in Vestibular Disease and Vestibular Function Disorder, sponsored by Université Catholique de Louvain. Completed at 1 site in Belgium. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Université Catholique de Louvain · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of this experiment is to gain a better understanding of the body movement patterns of patients with balance disorders (following damage to the vestibular system), as well as their cognitive performance profile. To achieve this, we will need to assess the performance of both patients and healthy subjects with no balance disorders. We will be using a newly-developed artificial intelligence tool to analyze body movement patterns on the basis of participants' videos, and we will also be evaluating participants' performance in a few simple tests of reaction times to image presentations on computer and/or tablet/smartphone.

If you agree to take part in this experiment, you will be asked to perform a simple walking exercise in a corridor (filmed and supervised by a physiotherapist) as well as a few objective cognitive measurement tests (reaction time to attentional and vigilance tasks on computer and/or tablet/smartphone) and subjective tests (self-reported questionnaires) requiring around 40 minutes of investigation in total.

In the long term, the results of this research will make it easier to assess balance disorders in patients with vestibular pathology, and better quantify any cognitive difficulties they may have.

02

Conditions studied

  • Vestibular Disease
  • Vestibular Function Disorder

Browse trials for

03

In context

Vestibular Diseases

175 studies on the registry are indexed under Vestibular Diseases; 41 are open to participants now.

This study's enrollment of 100 is above the median of 59 across 36 observational studies indexed under Vestibular Diseases.

Browse Vestibular Diseases studies →

Lead sponsor

Université Catholique de Louvain is the lead sponsor of 151 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical).

Eligibility criteria

For patients :

Inclusion Criteria:

  • Age between 18 and 90 years old.
  • Vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical).

Exclusion Criteria:

  • Previous neurological disorders (stroke, dementia, …)
  • Current medication interfering with the testing (reducing reaction time).
  • Visual difficulties interfering with the testing (Visual field reduction,…)
  • Age below 18 years old.

For healthy controls :

Inclusion criteria :

- Age between 18 and 90 years old.

Exclusion criteria:

  • Previous neurological disorders (stroke, dementia, …)
  • Current medication interfering with the testing (reducing reaction time)
  • Visual difficulties interfering with the testing (Visual field reduction,…)
  • Vertigo or balance complains or an history of previous vestibular disorder.
  • Age below 18 years old.
  • Not being able to understand the consigns of the task.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Vestibular

    Patients with vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical)

    Diagnostic Test: Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG)) · Diagnostic Test: Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.

  • Healthy controls

    People with no vestibular loss

    Diagnostic Test: Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG)) · Diagnostic Test: Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.

Interventions

  • Diagnostic testEvaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))

    To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters. Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task.

    Also known as: Neuropsychological assesment

  • Diagnostic testNeuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.

    Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).

06

What researchers measure

Primary outcomes

  1. Neuropsychological measures

    evaluation to assess attention (Test for Attentional Performance -TAP-) Alertness and Divided attention tasks. Median reaction time and standard deviation of the median (regularity) are record in milliseconds. Slow reaction times and large standard deviations indicate more difficulties.

    Time frame: Through the entire study, approximately 24 months

  2. Neuropsychological measures

    evaluation to assess quality-of-life (DHI -Dizziness Handicap Inventory, Jacobson \& Newman, 1990, Demanez 1991) 25-items, each scored on a 5-point Likert scale. Covering three main areas of difficulties: functional, physical, and emotional aspects related to dizziness and instability. Higher scores = higher complains

    Time frame: Through the entire study, approximately 24 months

  3. Neuropsychological measures

    evaluation to assess quality-of-life (Anxiety and depression symptoms, measured with the French version of the Hospital Anxiety and Depression Scale (HADS) (Zigmond \& Snaith, 1983), using a 14-item self-assessed questionnaire, each with a 4-point response Likert scale. Higher scores = higher complains

    Time frame: Through the entire study, approximately 24 months

  4. Neuropsychological measures

    evaluation to assess subjective perception of cognitive difficulties associated to vertigo with the Neuropsychological Vertigo Inventory - NVI (Lacroix et al., 2016), using 28-items, each scored on a 5-point Likert scale and divided into 7 distinct subscales measuring attention, memory, emotion, space perception, time perception, vision, and motor abilities. Higher scores = higher complains

    Time frame: Through the entire study, approximately 24 months

  5. Walking activity

    Participants performed the Timed-Up \& Go (TUG) four times (practice trial, normal, slow and fast speed). They have to stand up from a chair, walk until a line on the ground marked at 3 meters, turn, go back to the chair, and sit down again. The time is recorded. There is no time limit to the task.

    Time frame: Through the entire study, approximately 24 months

07

Study locations

1 site
  • Cliniques universitaires Saint-Luc
    Brussels, 1000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jul 2023, 22 months.

Of 18 observational studies under Vestibular Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 18, 2024
StartActual
Aug 10, 2021
Primary completionActual
Jul 1, 2023
CompletionActual
Jul 1, 2023
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06739577
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Aug 10, 2021
Primary completion
Jul 1, 2023
Completion
Jul 1, 2023
Last update
Dec 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion